Skip to main navigation Skip to search Skip to main content

CTU: PROCEADE PanTumor Master Protocol: A Phase 1b/2, Multicenter, Open-Label Study of the Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Solid Tumors [substudy - gastric, NSCLC, pancreatic]

  • Parsonson, Andrew (Primary Chief Investigator)
  • Armstrong, Emilia (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Quinlan, Gabriel (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • Garcia, Michelle (Clinical Trial Unit Staff)

Project: Research

Project Details

Description

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label
Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in
Participants With Advanced Solid Tumors (Master Protocol)

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label
Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in
Participants With Advanced Gastric Cancer (Substudy GC)

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label
Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in
Participants With Advanced Non-Small Cell Lung Cancer (Substudy NSCLC)

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label
Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in
Participants With Advanced Pancreatic Cancer (Substudy PDAC)

Short titleMS202329_0010
AcronymPROCEADE PanTumor
StatusFinished
Effective start/end date2/05/25 → 26/02/26